Answers are grounded in this paper and cite their sources.
Background/Objectives: Pediatric diffuse high-grade gliomas are defined by integrated molecular diagnosis, yet their immune microenvironment varies within diagnoses. We examined whether bulk transcriptomes resolve recurrent immune states, how these relate to diagnosis and location, and whether they carry prognostic information. Methods: RNA-sequencing data from 343 tumors in OpenPedCan v15 were profiled with LM22 deconvolution and 24 brain-tuned programs, then analyzed by consensus clustering, a continuous immune axis, reference-based deconvolution, external single-cell and spatial datasets, and Cox models. Results: Tumors occupied an ordered gradient summarized as Immune-high (n = 122), Immune-intermediate (n = 144), and Immune-low (n = 77) states. Every diagnosis contained multiple states, and molecular group explained 6.1% of immune-feature variance, with location adding 1.0%. The top genes separating Immune-high from Immune-low tumors were predominantly expressed by immune cells (98.0% versus 69.7% expected). Among 245 patients with 206 deaths, Immune-high status was associated with lower mortality (adjusted HR 0.62, 95% CI 0.42–0.91); this association attenuated after combined autopsy exclusion and RNA-library adjustment (HR 0.76, 0.45–1.29). Conclusions: Immune organization in pediatric diffuse high-grade glioma is a graded, diagnosis-modulated property whose prognostic value requires validation in uniformly processed diagnostic tissue.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: